StocksFin Logo
Fulgent Genetics, Inc. country of incorporation
|
|
Mr. Ming Hsieh
|
645 employees
NASDAQ | Healthcare | Diagnostics & Research
BioCryst Pharmaceuticals, Inc. country of incorporation
|
|
Mr. Jon Stonehouse
|
358 employees
NASDAQ | Healthcare | Biotechnology
Q322 reported Nov 7, 2022 Reporting Period
$105.66M -53.6% vs. Q321 Revenues Q322
43.63% -46.1% vs. Q321 Gross Profit Margin
1.63% -97% vs. Q321 Net Profit Margin
15.34M -89.9% vs. Q321 Free Cash Flow Q322
$0.06 -98.5% vs. Q321 EPS Q322
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q322
Q322
Q322 reported Nov 4, 2022 Reporting Period
$75.83M 85% vs. Q321 Revenues Q322
95.24% -3.3% vs. Q321 Gross Profit Margin
-56.08% ! 60.9% vs. Q321 Net Profit Margin
-32.62M ! -40.1% vs. Q321 Free Cash Flow Q322
$-0.23 ! 30.3% vs. Q321 EPS Q322
-
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q322
Q322
Loading...
Loading...
Ratios
As of
Sep 30, 2022
Sep 30, 2022
Quick Ratio
6.62
5.75
Current Ratio
6.79
6.23
Cash Ratio
1.65
3.02
Price to Book
0.9
-9.67
Price to Sales
10.89
30.94
Price to Earnings
167.28
-13.79